| Index | — | P/E | — | EPS (ttm) | -0.66 | Insider Own | 7.18% | Shs Outstand | 27.00M | Perf Week | -0.26% |
| Market Cap | 420.68M | Forward P/E | 6.53 | EPS next Y | 2.38 | Insider Trans | 0.00% | Shs Float | 24.50M | Perf Month | -5.46% |
| Enterprise Value | 794.68M | PEG | — | EPS next Q | -0.04 | Short Float | 2.44% | Perf Quarter | -22.22% | ||
| Income | -19.00M | P/S | 0.27 | EPS this Y | -91.59% | Short Ratio | 2.21 | Perf Half Y | -40.47% | ||
| Sales | 1.56B | P/B | 0.53 | EPS next Y | 1189.19% | ROA | -1.06% | Short Interest | 596.84K | Perf YTD | -9.94% |
| Book/sh | 29.52 | P/C | 60.11 | EPS next 5Y | — | ROE | -2.20% | 52W High | 26.73 -41.71% | Perf Year | -16.19% |
| Cash/sh | 0.26 | P/FCF | — | EPS past 3/5Y | -32.76% 1.88% | ROIC | -1.40% | 52W Low | 14.10 10.50% | Perf 3Y | -43.92% |
| Dividend Est. | 0.64 (4.11%) | EV/EBITDA | 10.89 | Sales past 3/5Y | -7.87% 5.62% | Gross Margin | 5.62% | Volatility | 3.28% 2.82% | Perf 5Y | -65.83% |
| Dividend TTM | 0.64 (4.11%) | EV/Sales | 0.51 | EPS Y/Y TTM | -123.22% | Oper. Margin | -1.42% | ATR (14) | 0.50 | Perf 10Y | -6.82% |
| Dividend Ex-Date | Aug 18, 2026 | Quick Ratio | 0.70 | Sales Y/Y TTM | 2.90% | Profit Margin | -1.14% | RSI (14) | 43.68 | Recom | 2.50 |
| Dividend Gr. 3/5Y | 5.83% — | Current Ratio | 1.28 | EPS Q/Q | -84.68% | SMA20 | -2.18% | Beta | 1.23 | Target Price | 30.80 |
| Payout | — | Debt/Eq | 0.48 | Sales Q/Q | 2.68% | SMA50 | -4.32% | Rel Volume | 0.85 | Prev Close | 15.53 |
| Employees | 1,410 | LT Debt/Eq | 0.48 | Earnings | Nov 04 | SMA200 | -20.11% | Avg Volume | 280.65K | Price | 15.58 |
| IPO Date | Sep 15, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -65.77% -6.80% | Net Debt/EBITDA | 5.12 | Volume | 237,599 | Change | 0.32% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Mar-12-26 | Reiterated | Loop Capital Markets | $25 | |
| Jan-15-26 | Initiated | Truist | Hold | $19 |
| May-19-25 | Upgrade | Piper Sandler | Neutral → Overweight | $39 → $32 |
| Apr-07-25 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Mar-18-25 | Reiterated | UBS | $39 → $35 | |
| Nov-08-24 | Reiterated | Piper Sandler | Overweight | $39 |
| Apr-09-24 | Reiterated | Stifel Nicolaus | Buy | $43 |
| Feb-06-19 | Downgrade | Cowen & Co. | Outperform → Market Perform |
AdvanSix Inc. operates as a global manufacturer and supplier of polymer resins, serving markets across the United States and internationally. A key offering is Nylon 6, a versatile synthetic polymer resin utilized in the production of fibers, filaments, specialized plastics, and films. The company's portfolio also includes caprolactam, an essential building block for other polymer resins, and ammonium sulfate fertilizers, which it distributes to farm cooperatives, retailers, and other channel partners. Furthermore, AdvanSix supplies acetone, a crucial ingredient for manufacturing adhesives, paints, coatings, solvents, herbicides, and engineered plastic resins. Its extensive range additionally comprises various intermediate chemicals, such as phenol, alpha-methyl styrene, cyclohexanone, methyl ethyl ketoxime, acetaldehyde oxime, 2-pentanone oxime, cyclohexanol, sulfuric acid, ammonia, and carbon dioxide. These offerings are marketed under established brands like Aegis, Capra, Sulf-N, Nadone, Naxol, and EZ-Blox. AdvanSix utilizes a dual sales approach, engaging directly with customers while also leveraging a network of distributors. The company, established in 2016, is headquartered in Parsippany, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,559 | 1,522 | 1,518 | 1,534 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,472 | 1,349 | 1,365 | 1,369 | — | — | — | — | — | |
| Gross Profit | 87 | 174 | 153 | 165 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 101 | 97 | 94 | 96 | — | — | — | — | — | |
| Research and Development | 0 | 9 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 9 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -22 | 68 | 59 | 70 | — | — | — | — | — | |
| Interest Expense | 9 | 8 | 11 | 7 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 11 | -5 | -2 | 7 | — | — | — | — | — | |
| Net Income Before Taxes | -21 | 54 | 46 | 69 | — | — | — | — | — | |
| Income Taxes | -3 | 5 | 1 | 15 | — | — | — | — | — | |
| Consolidated Net Income | -19 | 49 | 44 | 55 | — | — | — | — | — | |
| Net Income From Continuing Operations | -19 | 49 | 44 | 55 | — | — | — | — | — | |
| Net Income | -19 | 49 | 44 | 55 | — | — | — | — | — | |
| EPS (Recurring) | -0.66 | 1.83 | 1.65 | 2.00 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.66 | 1.83 | 1.65 | 2.00 | — | — | — | — | — | |
| EPS (Diluted) | -0.66 | 1.80 | 1.62 | 1.95 | — | — | — | — | — | |
| EBITDA | 73 | 143 | 133 | 150 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 9.61 | 17.59 | 15.36 | — | — | — | — | — | |
| Price To Sales Ratio | 0.27 | 0.31 | 0.51 | 0.53 | — | — | — | — | — | |
| Gross Margin | 5.58 | 11.43 | 10.08 | 10.76 | — | — | — | — | — | |
| Operating Margin | -1.41 | 4.47 | 3.89 | 4.56 | — | — | — | — | — | |
| Net Margin | -1.22 | 3.22 | 2.90 | 3.59 | — | — | — | — | — | |
| Shares Outstanding | 27 | 27 | 27 | 27 | — | — | — | — | — | |
| Market Capitalization | 421 | 467 | 769 | 809 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kintiroglou Achilles B. | SVP, General Counsel | Oct 03 '25 | Sale | 20.00 | 577 | 11,540 | 30,265 | Oct 03 |
| Kintiroglou Achilles B. | SVP, General Counsel | Sep 02 '25 | Sale | 21.20 | 571 | 12,105 | 30,842 | Sep 03 |
| Kintiroglou Achilles B. | SVP, General Counsel | Aug 01 '25 | Sale | 20.18 | 571 | 11,523 | 31,413 | Aug 04 |
| Kintiroglou Achilles B. | SVP, General Counsel | Jul 02 '25 | Sale | 24.85 | 571 | 14,189 | 31,984 | Jul 02 |
| Kintiroglou Achilles B. | SVP, General Counsel | Jun 02 '25 | Sale | 23.65 | 571 | 13,504 | 32,555 | Jun 04 |
| Kintiroglou Achilles B. | SVP, General Counsel | May 01 '25 | Sale | 21.34 | 3,237 | 69,078 | 33,126 | May 05 |
| Kintiroglou Achilles B. | SVP, General Counsel | Apr 01 '25 | Sale | 22.24 | 4,000 | 88,960 | 36,363 | Apr 01 |
| Kintiroglou Achilles B. | SVP, General Counsel | Mar 03 '25 | Sale | 27.75 | 4,000 | 111,000 | 40,363 | Mar 04 |
| Kane Erin N | Chief Executive Officer | Feb 03 '25 | Sale | 30.19 | 5,000 | 150,954 | 502,795 | Feb 04 |
| Kane Erin N | Chief Executive Officer | Jan 02 '25 | Sale | 28.15 | 5,000 | 140,740 | 507,795 | Jan 03 |
| Kane Erin N | Chief Executive Officer | Dec 02 '24 | Sale | 32.29 | 5,000 | 161,450 | 512,795 | Dec 04 |
| Gramm Christopher | Controller | Nov 25 '24 | Option Exercise | 14.29 | 1,951 | 27,880 | 45,414 | Nov 26 |
| Gramm Christopher | Controller | Nov 25 '24 | Sale | 32.00 | 1,951 | 62,432 | 43,463 | Nov 26 |
| NEWMAN DONALD P | Director | Nov 18 '24 | Buy | 29.64 | 5,030 | 149,089 | 5,030 | Nov 19 |
| Gramm Christopher | Controller | Nov 07 '24 | Option Exercise | 14.29 | 505 | 7,216 | 43,968 | Nov 08 |